Recent Quotes (30 days)

You have no recent quotes
chg | %

Avivagen Inc  

(Public, CVE:VIV)   Watch this stock  
Find more results for CVE:CFR
-0.0050 (-6.67%)
Jan 28 - Close
CVE data delayed by 15 mins - Disclaimer
Currency in CAD
Range 0.07 - 0.07
52 week 0.05 - 0.10
Open 0.07
Vol / Avg. 35,500.00/152,364.00
Mkt cap 13.75M
P/E     -
Div/yield     -
EPS -0.01
Shares 196.38M
Beta 0.39
Inst. own     -

Key stats and ratios

Q4 (Oct '14) 2014
Net profit margin -1355.33% -703.62%
Operating margin -1355.33% -703.62%
EBITD margin - -692.42%
Return on average assets -215.92% -183.25%
Return on average equity - -
CDP Score - -


100 Sussex Drive
+1-613-9498164 (Phone)
+1-613-9930796 (Fax)

Website links


Avivagen Inc. is a development-stage biotechnology company. The Company is focused on bringing forward products based on its OxC-Beta (oxidized carotenoid) technology, to assist in optimizing health and feed animals. The Company is developing OxC-Beta as a non-antibiotic alternative feed additive for promoting health and productivity. OxC-Beta, is obtained via spontaneous, full oxidation of Beta-carotene. Its Vivamune consists of packages of 30 chews in two sizes for dogs and one for cats. Health Chews, Its Oximunol Chewables and Vivamune Health Chews contain mixtures of carotenoids and carotenoid oxidation products.

Officers and directors

Cameron Groome President, Chief Executive Officer
Chris Boland Chief Financial Officer
Janusz Daroszewski Managing Director - Chemistry and Technical Support, Director
David Hankinson Executive Director
Graham Burton Director - Commercialization Science, Director
Amin I. Khalifa Independent Director
Chandra J. Panchal Ph.D. Independent Director